LYUMJEV
Clinical safety rating: caution
Comprehensive clinical and safety monograph for LYUMJEV (LYUMJEV).
LYUMJEV (insulin lispro-aabc) is a rapid-acting insulin analog that binds to the insulin receptor (IR), activating the IR tyrosine kinase cascade. This leads to increased glucose uptake in peripheral tissues (primarily skeletal muscle and adipose tissue), inhibition of hepatic gluconeogenesis, and promotion of glycogen synthesis. The aabc amino acid substitution (insulin lispro with proline at B28 replaced by lysine and lysine at B29 replaced by proline, plus an additional modification) results in faster dissociation from the insulin receptor and accelerated absorption from subcutaneous tissue compared to regular human insulin.
| Metabolism | LYUMJEV is metabolized primarily by insulin-degrading enzyme (IDE). A small amount of metabolism also occurs via hepatic clearance by receptor-mediated endocytosis and subsequent degradation. The metabolic pathways do not involve cytochrome P450 enzymes. |
| Excretion | Primarily renal; approximately 90% of absorbed dose is excreted via urine as metabolites and unchanged drug, with the remainder eliminated in feces (<10%). |
| Half-life | Terminal elimination half-life of LYUMJEV (insulin lispro) is approximately 13.7 minutes (0.23 hours) in healthy subjects, reflecting rapid clearance from the bloodstream. |
| Protein binding | Weakly bound to serum proteins (primarily albumin); less than 10% bound. |
| Volume of Distribution | Approximately 0.26-0.37 L/kg, indicating distribution primarily within extracellular fluid. |
| Bioavailability | Subcutaneous: 55-77% (mean ~70%), due to local degradation prior to absorption. |
| Onset of Action | Subcutaneous injection: 15-30 minutes (peak insulin concentration occurs at 30-90 minutes). |
| Duration of Action | 3-5 hours for subcutaneous injection, with a dose-dependent duration; typically used to cover prandial insulin needs. |
Subcutaneous injection at mealtime (within 15 minutes before or immediately after meal). Doses individualized; typical range 0.2-1.0 units/kg/day.
| Dosage form | INJECTABLE |
| Renal impairment | No dose adjustment required for renal impairment. Closely monitor blood glucose. |
| Liver impairment | No specific Child-Pugh based guidelines. Consider reduced doses due to impaired gluconeogenesis and increased hypoglycemia risk. |
| Pediatric use | Children 6-17 years: individualized based on weight and metabolic needs; typical starting dose 0.2-0.5 units/kg/day. Children <6 years: safety and efficacy not established. |
| Geriatric use | Initiate at lower doses (e.g., 0.2-0.4 units/kg/day) due to increased risk of hypoglycemia; titrate cautiously. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for LYUMJEV (LYUMJEV).
| Breastfeeding | Insulin lispro is excreted into human milk in small amounts (M/P ratio not established). It is a protein that is likely digested in the infant's GI tract. Considered compatible with breastfeeding; monitor infant for hypoglycemia. |
| Teratogenic Risk | Insulin lispro (LYUMJEV) does not cross the placenta in significant amounts. There is no evidence of teratogenicity; however, poorly controlled diabetes increases risks of congenital anomalies, macrosomia, and neonatal hypoglycemia. Use during pregnancy requires careful glucose control. |
■ FDA Black Box Warning
None
| Serious Effects |
["Hypersensitivity to insulin lispro-aabc or any excipients in LYUMJEV","During episodes of hypoglycemia"]
| Precautions | ["Hypoglycemia: Severe, life-threatening hypoglycemia can occur, especially with changes in insulin dose, meal patterns, or exercise.","Hypokalemia: Insulin can cause rapid shifts of potassium into cells, leading to hypokalemia; monitor potassium levels.","Fluid retention and heart failure: Concomitant use with thiazolidinediones (TZDs) may increase risk of fluid retention and heart failure.","Hyperglycemia or ketoacidosis: Risk is increased with missed doses, illness, or changes in insulin regimen.","Medication errors: LYUMJEV is a rapid-acting insulin and should not be mixed with other insulins or used in insulin pumps (not approved for pump use).","Hypersensitivity: Generalized allergic reactions including anaphylaxis and angioedema have been reported."] |
| Food/Dietary | No specific food interactions. Dose should be adjusted based on carbohydrate intake and blood glucose monitoring. Alcohol may increase risk of hypoglycemia; advise caution. |
Loading safety data…
| Fetal Monitoring |
| Monitor blood glucose frequently (pre- and postprandial). Fetal monitoring: ultrasound for growth and anatomy, nonstress tests, and biophysical profile in third trimester. Assess for maternal hypoglycemia and ketoacidosis. |
| Fertility Effects | No known adverse effects on fertility. Poor glycemic control may impair fertility; optimizing glucose control improves fertility outcomes. |
| Clinical Pearls | LYUMJEV (insulin lispro-aabc) is a rapid-acting insulin analog with a faster onset than insulin lispro (Humalog). Administer within 0-2 minutes before a meal or immediately after if needed. Use only U-100 insulin syringes or compatible pens. Do not mix with insulins containing zinc (e.g., NPH) due to precipitation risk. Monitor for hypoglycemia, especially when switching from other insulins. Not recommended for use in insulin pumps unless specified as compatible. |
| Patient Advice | Inject LYUMJEV within 0-2 minutes before starting a meal, or immediately after eating if necessary. · Rotate injection sites within the same area (abdomen, thigh, upper arm) to reduce lipodystrophy. · Do not share pens or syringes with others. · Keep unopened pens in the refrigerator; once in use, store at room temperature for up to 28 days. · Recognize symptoms of hypoglycemia (sweating, tremor, confusion) and treat with fast-acting glucose. · Do not use if solution is cloudy or contains particles. |